Moderna will begin testing its Covid vaccine on adolescents aged 12 to 17

EU reaches deal with Moderna for quicker vaccine supply

EU reaches deal with Moderna for quicker vaccine supply. Credit: Moderna Press Centre

MODERNA will begin testing its Covid vaccine on adolescents aged 12 to 17 in the US, according to reports on Thursday, December 3.

The Moderna company will begin to evaluate the efficacy and safety of its vaccine against COVID-19 in adolescents between the ages of 12 and 17, as reported in the United States clinical trials portal (clinicaltrials.gov) and The New York Times.

The study will include 3,000 adolescents, of whom half will receive two injections of the vaccine four weeks apart and the other half a placebo.

The trial “is not yet recruiting” participants and there is still no start date, Colleen Hussey, a spokeswoman for Moderna, told the US newspaper.


Thank you for taking the time to read this news article “Moderna will begin testing its Covid vaccine on adolescents aged 12 to 17”. For more UK daily news, Spanish daily news and Global news stories, visit the Euro Weekly News home page.

Written by

Matthew Roscoe

Originally from the UK, Matthew is based on the Costa Blanca and is a web reporter for The Euro Weekly News covering international and Spanish national news. Got a news story you want to share? Then get in touch at editorial@euroweeklynews.com.

Comments